EP0983289A4 - Oligonukleotidhilfsmittel - Google Patents

Oligonukleotidhilfsmittel

Info

Publication number
EP0983289A4
EP0983289A4 EP98923657A EP98923657A EP0983289A4 EP 0983289 A4 EP0983289 A4 EP 0983289A4 EP 98923657 A EP98923657 A EP 98923657A EP 98923657 A EP98923657 A EP 98923657A EP 0983289 A4 EP0983289 A4 EP 0983289A4
Authority
EP
European Patent Office
Prior art keywords
oligonucleotide adjuvant
oligonucleotide
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98923657A
Other languages
English (en)
French (fr)
Other versions
EP0983289A1 (de
Inventor
Michael J Caulfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0983289A1 publication Critical patent/EP0983289A1/de
Publication of EP0983289A4 publication Critical patent/EP0983289A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
EP98923657A 1997-05-19 1998-05-19 Oligonukleotidhilfsmittel Withdrawn EP0983289A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4712197P 1997-05-19 1997-05-19
US47121P 1997-05-19
PCT/US1998/010459 WO1998052962A1 (en) 1997-05-19 1998-05-19 Oligonucleotide adjuvant

Publications (2)

Publication Number Publication Date
EP0983289A1 EP0983289A1 (de) 2000-03-08
EP0983289A4 true EP0983289A4 (de) 2001-04-25

Family

ID=21947178

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98923657A Withdrawn EP0983289A4 (de) 1997-05-19 1998-05-19 Oligonukleotidhilfsmittel

Country Status (5)

Country Link
EP (1) EP0983289A4 (de)
JP (1) JP2001526688A (de)
AU (1) AU7589398A (de)
CA (1) CA2289741A1 (de)
WO (1) WO1998052962A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0930893B1 (de) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulierende oligonucleotidekonjugate
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
JP4101888B2 (ja) 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
EP1009413B1 (de) 1997-09-05 2007-02-14 The Regents Of The University Of California Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
US7029680B1 (en) 1998-02-03 2006-04-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Delivery of immunogenic molecules vis HBsAg particles
WO1999039736A2 (en) * 1998-02-03 1999-08-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem DELIVERY OF IMMUNOGENIC MOLECULES VIA HBsAg PARTICLES
IL139813A0 (en) * 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
DE60041335D1 (de) 1999-08-19 2009-02-26 Dynavax Tech Corp Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
FR2805265B1 (fr) * 2000-02-18 2002-04-12 Aventis Pasteur Oligonucleotides immunostimulants
FR2805264B1 (fr) * 2000-02-18 2002-04-12 Aventis Pasteur Oligonucleotides immunostimulants
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
AU2002231336B2 (en) 2000-12-27 2007-06-28 Surefire Medical, Inc. D/B/A Trisalus Life Sciences Immunomodulatory polynucleotides and methods of using the same
US8114418B2 (en) 2001-06-21 2012-02-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—IV
WO2003014316A2 (en) 2001-08-07 2003-02-20 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
CN1604795B (zh) 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
WO2004011650A2 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
ES2381309T3 (es) 2002-12-23 2012-05-25 Dynavax Technologies Corporation Secuencia de oligonucleótidos inmunoestimuladores y métodos para usar los mismos
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7704514B2 (en) 2003-03-24 2010-04-27 Intercell Ag Vaccines
DE602005020815D1 (de) 2004-09-24 2010-06-02 Intercell Ag Verändertes vp-1capsidprotein von parvovirus b19
KR101251707B1 (ko) 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
CA2792258A1 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
DK2812434T3 (en) * 2012-02-09 2018-07-16 Bavarian Nordic As AGONISTS AND ANTAGONISTS OF TOLL-LIKE RECEPTOR-13 (TLR-13)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468520A2 (de) * 1990-07-27 1992-01-29 MITSUI TOATSU CHEMICALS, Inc. Palindromische DNS-Sequenz enthaltende immunostimulierende Mittel

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535905D1 (de) * 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468520A2 (de) * 1990-07-27 1992-01-29 MITSUI TOATSU CHEMICALS, Inc. Palindromische DNS-Sequenz enthaltende immunostimulierende Mittel

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KLINMAN D M ET AL: "CONTRIBUTION OF CPG MOTIFS TO THE IMMUNOGENICITY OF DNA VACCINES", JOURNAL OF IMMUNOLOGY,THE WILLIAMS AND WILKINS CO. BALTIMORE,US, vol. 158, 1 April 1997 (1997-04-01), pages 3635 - 3639, XP002910242, ISSN: 0022-1767 *
See also references of WO9852962A1 *

Also Published As

Publication number Publication date
JP2001526688A (ja) 2001-12-18
EP0983289A1 (de) 2000-03-08
CA2289741A1 (en) 1998-11-26
WO1998052962A1 (en) 1998-11-26
AU7589398A (en) 1998-12-11

Similar Documents

Publication Publication Date Title
EP0983289A4 (de) Oligonukleotidhilfsmittel
DE69840172D1 (de) Rna exportelement
NO20003303D0 (no) Vaksine
DE69831181D1 (de) Positionsbestimmung
DE69832354D1 (de) Netzwerkverwaltungsrahmwerk
DE69837412D1 (de) Ventilpositioniersystem
DE69836650D1 (de) Fuseanordnung
DE69833054D1 (de) Tintenzuführsystemadapter
DE69815551D1 (de) Acrylatcopolymerfasern
DE69823440D1 (de) Mikroskopeichung
DE69817568D1 (de) Elektrochemilumineszenzdetektor
DE69709052D1 (de) Haarklip
DE69834236D1 (de) Karteneinführmechnismus
IT1305521B1 (it) Limitatore di coppia
DE69816619D1 (de) Brennkraftemaschine
DE69803771D1 (de) Polysiloxanpolyole
DE69822175D1 (de) Reibe
DE69816767D1 (de) Polklemme
DE69810954D1 (de) 7-methyliden-5-oxo-kondensierte naphtopyrane
DE69824811D1 (de) Propelleraxiallager
DE69822025D1 (de) Schmelzfixierrollengehäuse
DE69818756D1 (de) Aufwickelspulenverriegelungsmechanismus
DE69814620D1 (de) Kippsegmentaxiallager
ATA111897A (de) Kimme
DE69804431D1 (de) Ausgangszeitbasiskorrelator

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010308

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07H 21/00 A, 7C 07H 21/04 B, 7A 61K 48/00 B, 7A 61K 31/7088 B, 7A 61K 31/7125 B

17Q First examination report despatched

Effective date: 20020125

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020605